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Key messages
 ► This nationwide cohort study reports a strong as-
sociation between the long course (10 days) of oral 
corticosteroid (OCS) treatment and the sustained 
increase in risk of admission with pneumonia and 
all-cause mortality—up to 1 year after exposure—in 
outpatients with chronic obstructive pulmonary dis-
ease as compared with a short course (5 days) of 
OCS.
 ► There was a time-dependent change in the mag-
nitude of risk: those with current exposure had a 
higher vulnerability to pneumonia and all-cause 
mortality.
 ► Understanding how risk depends on patterns of 
OCS will contribute to improved benefits and harm 
assessment.
AbstrAct
Introduction A large group of patients with chronic 
obstructive pulmonary disease (COPD) are exposed to 
an overload of oral corticosteroids (OCS) due to repeated 
exacerbations. This is associated with potential serious 
adverse effects. Therefore, we evaluated the impact of a 
recommended reduction of OCS duration in 2014 on the 
risk of pneumonia hospitalisation and all-cause mortality in 
patients with acute exacerbation of COPD (AECOPD).
Methods This was a nationwide observational cohort 
study that was based on linked administrative registry data 
between 1 January 2010 and 31 October 2017. 10 152 
outpatients with COPD (median age 70 years) treated with 
either a short (≤250 mg) or long course (>250 mg) of OCS 
for AECOPD were included in the study. Cox proportional 
hazards regression models were used to derive an 
estimation of multivariable adjusted HRs (aHRs) for 
pneumonia hospitalisation or all-cause mortality combined 
and pneumonia hospitalisation and all-cause mortality, 
separately.
results The long course of OCS treatment for AECOPD 
was associated with an increased 1-year risk of 
pneumonia hospitalisation or all-cause mortality (aHR 1.3, 
95% CI 1.1 to 1.4; p<0.0001), pneumonia hospitalisation 
(aHR 1.2, 95% CI 1.0 to 1.3; p=0.0110) and all-cause 
mortality (aHR 1.8, 95% CI 1.5 to 2.2; p<0.0001) as 
compared with the short course of OCS treatment. These 
results were confirmed in several sensitivity analyses.
conclusion The change of recommendations from long 
courses to short courses of OCS for AECOPD in 2014 
was strongly associated with a decrease in pneumonia 
admissions and all-cause mortality, in favour of short 
courses of OCS.
IntroductIon
Exacerbations of chronic obstructive pulmo-
nary disease (COPD) contribute to high 
morbidity and mortality.1 Patients with COPD 
are also at greater risk of developing pneu-
monia, mainly due to the impairment of lung 
defence mechanisms and use of inhaled corti-
costeroids (ICS).2 In addition, patients hospi-
talised for COPD and pneumonia exhibit 
substantially higher rates of intensive care 
admission, mortality and longer length of 
hospital stay compared with persons without 
COPD.3
Global Initiative for Chronic Obstructive 
Lung Disease (GOLD) recommendation for 
treatment duration of systemic corticosteroids 
(oral corticosteroids, OCS) for acute exacer-
bations of COPD (AECOPD) has changed 
over the last decades, ranging from treatment 
durations of 10–14 days,4 7–10 days5 and is 
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currently 5–7 days. The last reduction was based on a 
robust randomised controlled trial.6
OCS are recommended to patients with COPD during 
acute exacerbations, and most COPD exacerbations can 
safely be managed in the outpatient setting.7 OCS have 
been found to shorten the length of hospital stays, improve 
lung function, and reduce the risk of early relapse and 
treatment failure in patients with non-pneumonia exac-
erbation. No effect has been observed regarding longer-
term lung function, length of stay at intensive care unit 
and 30-day mortality.8 Most clinical trials investigating 
OCS for exacerbations were performed on patients who 
require hospitalisation, and only a few have described the 
effect of OCS in the outpatient setting.
OCS use is associated with a number of adverse effects 
including hyperglycaemia, fluid retention, weight gain, 
hypertension, diabetes mellitus, adrenal suppression, 
deep vein thrombosis, osteoporosis and increased frac-
ture risk.8 9 Even short courses of OCS (median days=6) 
have been associated with adverse effects, and they 
increase with increased number of OCS courses.10 11 In 
addition, OCS have been shown to cause severe infec-
tions due to their immunosuppressive activity, which 
impairs phagocyte function and suppresses cell-mediated 
immunity.12 This was confirmed in a meta-analysis of 71 
pooled controlled trials that showed a relative risk of 1.6 
for infectious events in the prednisolone group (n=2111) 
compared with the controls (n=2087).13 However, the 
risk of severe infections and death following the use 
of OCS is in general unknown and mainly short-term 
follow-up endpoints have been reported in patients with 
COPD. Therefore, we conducted a nationwide, observa-
tional cohort study to determine the association between 
duration of OCS treatment in outpatients with AECOPD 
and the risk of pneumonia hospitalisation and all-cause 
mortality during a 1-year study period and to explore how 
the timing of the exposure affects the risk estimates.
Methods
data sources and covariates
The following nationwide registers were used to link on 
an individual level:
1. The Danish Register of Chronic Obstructive Pulmonary 
Disease (DrCOPD) is a nationwide database that con-
tains information on the quality of treatment of all pa-
tients with COPD in Denmark.14 All Danish hospitals, 
since 2008, that treat patients with COPD report to the 
register. Covariates included in this study were age, 
lung function—assessed as FEV1% predicted, body 
mass index—assessed as kilograms per square me-
tre, dyspnoea—assessed using the Medical Research 
Council (MRC) Dyspnoea Scale, smoking status, ICS, 
and long-acting β2-agonist (LABA) or long-acting 
muscarinic antagonist use.
2. The Danish National Patient Registry (DNPR), which 
holds information on all admissions to Danish hospi-
tals, since 1977, and hospital outpatient clinic visits, 
since 1995. Each hospital visit is coded by physicians 
with one primary diagnosis and one or more second-
ary diagnoses, according to the International Classifi-
cation of Diseases, eighth revision (ICD-8) codes until 
1994 and ICD-10 thereafter.15 Covariates included ex-
acerbations in the previous year, essential hyperten-
sion, diabetes mellitus, myocardial infarction, atrial 
fibrillation, heart failure, peripheral vascular disease, 
cerebrovascular disease, renal failure and depression 
(table 1 and online supplementary table s1).
3. The Danish National Health Service Prescription Da-
tabase (DNHSPD) holds information on all prescrip-
tions that have been dispensed in Danish pharmacies, 
since 2004 (coded according to the Anatomical Ther-
apeutic Chemical (ATC) classification system), includ-
ing the following information in terms of OCS: the 
date of dispensation, the quantity dispensed as well as 
the strength and formulation of all prescriptions that 
have been dispensed from Danish Pharmacies. All 
pharmacies are required by Danish legislation to pro-
vide information that ensures complete and accurate 
registration.16
4. The Danish Civil Registration System (CRS) includes 
individual information on the unique personal iden-
tification number, name, sex, date of birth and vital 
status.17
study desIgn
Danish residents who were registered with a diagnosis of 
COPD between 1 January 2010 and 31 October 2017 were 
identified in the DrCOPD. We formed the base cohort by 
linking these individuals with prednisolone prescriptions 
(ATC code H02AB06) for the treatment of AECOPD in 
the outpatient clinic in the DNHSPD. We chose not to 
include prednisone (ATC code H02AB07) as they were 
given for other indications. Patients were excluded if they 
did not receive prednisolone prescription, ever had an 
asthma diagnosis or had received prednisolone prescrip-
tion above 2500 mg as these have been prescribed as 
maintenance treatment for stable patients with COPD. 
The study cohort was followed from prescription date to 
the occurrence of hospitalisation for pneumonia, death 
or 1 year from OCS prescription (figure 1 and online 
supplementary figure s2).
Patients were stratified into two groups: (i) Prednisolone 
prescriptions below or equal to 250 mg, correspond to a 
short course of OCS (a package of 10 pieces of 25 mg given 
for a 5-day treatment with 37.5 mg daily). (ii) Prednisolone 
prescriptions above 250 mg, corresponding to a long course 
of OCS (two or more packages of 10 pieces of 25 mg given 
for a 10-day treatment with 37.5 mg daily). This definition 
of long and short courses was based on Danish guidelines 
and prednisolone prescription practice. The change of 
OCS duration recommendation in 2014 made it possible 
for us to compare the treatments short course versus long 
course in the periods before (2010-2013) versus after (2014-
2017) recommendation change (supplementary figure s3). 
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Table 1 Baseline characteristics of outpatients with COPD who were treated with short vs long course of OCS during the 
period of January 2010 to October 2017
Characteristics All (n=10 152) Short course (n=6002) Long course (n=4150)
Demographics
Age, median (IQR) 70 (63–77) 70 (62–76) 70 (63–77)
Age≤62 2456 (24.2) 1528 (25.5) 928 (22.4)
63–70 2835 (27.9) 1670 (27.8) 1165 (28.1)
71–77 2586 (25.5) 1523 (25.4) 1063 (25.6)
≥78 2275 (22.4) 1281 (21.3) 994 (23.9)
Male 5095 (50.2) 2962 (49.4) 2133 (51.4)
MRC, n/median (IQR) 3 (2–4) 3 (2–4) 3 (2–4)
FEV1≥80% 451 (5.3) 251 (4.9) 200 (5.8)
50%≤FEV1<80% 3523 (41.1) 2176 (42.3) 1347 (39.3)
30%<FEV1<50% 3310 (38.6) 2220 (39.3) 1290 (37.6)
FEV≤30% 1289 (15.0) 698 (13.5) 593 (17.3)
Exacerbations within the past year 0 4601 (76.7) 3176 (76.5)
1 1011 (16.8) 669 (16.1)
≥2 390 (6.5) 305 (7.4)
Inhaled corticosteroids 7320 (72.1) 4361 (72.7) 2959 (71.3)
Inhaled LABA or LAMA 8781 (86.5) 5233 (87.2) 3548 (85.5)
BMI, median (IQR) 25 (21.3–29) 25 (21.1–29) 25 (21.5–29)
BMI (kg/m2)
  10.0–18.4 706 (8.2) 416 (8.1) 290 (8.4)
  18.5–24.9 3400 (39.7) 2003 (39.2) 1397 (40.4)
  25.0–29.9 4464 (52.1) 2693 (52.7) 1771 (51.2)
Total dose OCS (mg), median (IQR) 250 (250–500) 250 (250–250) 500 (500–1000)
Smoking
  Current smokers 3264 (32.2) 2030 (33.8) 1234 (29.7)
  Ex-smokers/non-smokers 5253 (51.7) 3075 (51.2) 2178 (52.5)
Missing data 1635 (16.1) 897 (15.0) 738 (17.8)
Comorbidities
  Heart failure 2075 (20.4) 1194 (19.9) 881 (21.2)
  Atrial fibrillation 2341 (23.1) 1350 (22.5) 991 (23.9)
  Myocardial infarction 1197 (11.8) 701 (11.7) 496 (11.9)
  Hypertension 4215 (41.5) 2473 (41.2) 1742 (42.0)
  Diabetes mellitus 1391 (13.7) 789 (13.2) 602 (14.5)
  Peripheral vascular disease 1783 (17.6) 1046 (17.4) 737 (17.8)
  Cerebrovascular disease 1592 (15.7) 900 (15.0) 692 (16.7)
  Renal failure 866 (8.5) 484 (8.1) 382 (9.2)
  Depression 669 (6.6) 395 (6.6) 274 (6.6)
Data are presented as n (%) unless otherwise stated.
BMI, body mass index; COPD, chronic obstructive pulmonary disease; LABA, long-acting β2-agonist; LAMA, long-acting muscarinic 
antagonist; MRC, Medical Research Council Dyspnoea Scale; OCS, oral corticosteroids.
Both treatments were given during their respective periods 
as first line treatments – providing a comparison that miti-
gates the possibility that long course was given for the 
most severity of COPD patients. The study was approved 
by the Danish Data Protection Agency (journal number: 
HGH-2017-091, with I-Suite no.: 05884).
Patient and public involvement
Patients were not involved in the design of this study.
outcomes
The outcomes of interest were admission with pneu-
monia and all-cause mortality. These were investigated 
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Figure 1 Study flowchart. AECOPD, acute exacerbations 
of chronic obstructive pulmonary disease; DNHSPD, Danish 
National Health Service Prescription Database; DrCOPD, 
Danish Register of Chronic Obstructive Pulmonary Disease; 
OCS, oral corticosteroids.
Table 2 Pneumonia hospitalisation or all-cause mortality 
(combined endpoint)
Adjusted HR (95% CI)
Time from exposure
  1 month 1.6 (1.1 to 2.2)
  3 months 1.3 (1.1 to 1.7)
  6 months 1.3 (1.2 to 1.6)
  1 year 1.3 (1.1 to 1.4)
Time from exposure above day 30
  1 months –
  3 months 1.2 (1.0 to 1.6)
  6 months 1.3 (1.2 to 1.6)
  1 year 1.3 (1.1 to 1.4)
First part: Adjusted HRs (aHRs) for pneumonia hospitalisation or 
all-cause mortality for outpatients with acute exacerbations of 
chronic obstructive pulmonary disease who were treated with a 
long-course oral corticosteroid (OCS) treatment during the 1-year 
follow-up. Second part: aHRs where we are not counting for any 
events before day 30. The reference group was the short-course 
OCS treatment. All analyses were adjusted for age, sex, inhaled 
corticosteroids, smoking status, calendar year, FEV1% predicted, 
Medical Research Council Dyspnoea Scale, body mass index, 
heart failure, atrial fibrillation, myocardial infarction, hypertension, 
diabetes mellitus, peripheral vascular disease, cerebrovascular 
disease, renal failure and depression.
Table 3 Pneumonia hospitalisation and all-cause mortality 
(separate endpoints)
Time from exposure Adjusted HR (95% CI)
Pneumonia hospitalisation
  1 month 1.4 (1.0 to 2.2)
  3 months 1.2 (1.0 to 1.6)
  6 months 1.2 (1.0 to 1.4)
  1 year 1.2 (1.0 to 1.3)
All-cause mortality
  1 month 5.1 (1.7 to 15.6)
  3 months 2.5 (1.5 to 4.3)
  6 months 2.0 (1.5 to 2.6)
  1 year 1.8 (1.5 to 2.2)
Secondary endpoints: Adjusted hazard ratios (aHR) of pneumonia 
hospitalisation and all-cause mortality for outpatients with acute 
exacerbations of chronic obstructive pulmonary disease who were 
treated with a long-course oral corticosteroid (OCS) treatment 
during the 1-year follow-up. The reference group was the short-
course OCS treatment. All analyses were adjusted for age, sex, 
inhaled corticosteroids, smoking status, calendar year, FEV1% 
predicted, Medical Research Council Dyspnoea Scale, body 
mass index, heart failure, atrial fibrillation, myocardial infarction, 
hypertension, diabetes mellitus, peripheral vascular disease, 
cerebrovascular disease, renal failure and depression.
both as a combined endpoint (pneumonia hospitalisa-
tion or all-cause mortality) and individual endpoints. The 
combined endpoint was chosen as the primary endpoint. 
Admissions with pneumonia were identified by DNPR 
registry data (primary diagnosis of pneumonia and no 
requirement for a secondary diagnosis) (figure 1). The 
diagnosis of pneumonia was based on ICD codes (DJ12 
to DJ18) from hospitalisation. In Denmark, the National 
guideline on pneumonia states that such a diagnosis 
includes (obligatory) a novel infiltrate on a chest X-ray. 
All the participating departments refer to this definition. 
The mortality date was specified in the CRS. The date of 
the first OCS exposure was defined as the index date.
statistical analysis
For descriptive statistics, continuous variables were 
presented as median values and IQRs, and categorical 
variables as frequencies and proportions. For compar-
ison, we used the Mann-Whitney U test for continuous 
variables and the χ2 test for dichotomous variables. Using 
the Aalen-Johansen estimator, we performed a cumula-
tive incidence plot of the first pneumonia hospitalisation 
and all-cause mortality stratified on short versus long 
course of OCS. We used the log-rank test for the equiv-
alence of the cumulative incidence curves. Cox propor-
tional hazards regression analyses were fitted to assess the 
risk of pneumonia hospitalisation or all-cause mortality at 
1, 3, 6 months and 1 year, respectively, after a long course 
of OCS treatment as compared with the short course 
of OCS treatment. An adjusted analysis including age, 
sex, smoking, calendar year, MRC dyspnoea score, BMI, 
FEV1% predicted, ICS therapy and all the nine comor-
bidities was performed to ensure that the results were not 
due to these potential confounding factors (tables 2 and 
3). The results were presented as HRs with 95% confi-
dence limits (CI).
In another sensitivity analyses, in order to reduce 
potential effects of confounding in the case of a greater 
number of prescriptions in one group, patients were 
censored prior to receiving the second OCS. The purpose 
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Figure 2 Cumulative incidence curves for the three outcomes among COPD outpatients treated with long vs short course of 
OCS, 2010–2017 (P<0.0001).
of this was to avoid the effect of an accumulated dose of 
prednisolone on the outcome.
Because exposure to OCS varied over time in the 
cohort, a nested case–control model was used to calcu-
late the OR for pneumonia hospitalisation. The date 
of the first admission for pneumonia during follow-up 
was considered as the date of the event (index date). 
Cases with a pneumonia hospitalisation were matched, 
one control each at the time of pneumonia by age, 
sex, FEV1% predicted and smoking (current smoker vs 
ex-smoker/non-smoker), which was measured 1 year 
before the index date by using risk set sampling to assure 
that the match occurred before death and pneumonia 
hospitalisation in the controls. Neither the cases nor the 
controls were reused in the analysis. OCS exposure was 
defined as binary variable: short course (≤250 mg) versus 
long course (>250 mg). The same analysis was performed 
for all-cause mortality. Matching was performed with 
some loss in statistical power. Statistical analyses were 
performed using SAS statistical software V.9.4 (SAS Insti-
tute, Cary, North Carolina, USA) and R statistical software 
(V.3.4.3). SAS and R codes were reviewed by an indepen-
dent statistician.
results
The baseline characteristics of the two groups are 
presented in table 1. A total of 10 152 patients with COPD 
(median age 70 years; 50.2% male) who were treated with 
OCS were identified from the 67 208 patients with COPD 
in the sampling cohort between 1 January 2010 and 31 
October 2017 (figure 1). The number of patients who 
received short and long course of OCS was 6002 (59.1%) 
and 4150 (40.9%), respectively. The patients in the short-
course and long-course groups were similar, overall, with 
no clinically significant differences in their characteris-
tics (table 1).
Main analyses
Risk associated with the use of long versus short courses of OCS
Cumulative incidence curves for estimating the prob-
ability of pneumonia hospitalisation and all-cause 
mortality, over time, are presented in figure 2. Signif-
icant differences were found between the two groups 
(p<0.0001, using log-rank test). After 1-year follow-up, 
the cumulative incidence of pneumonia hospitalisation 
and all-cause mortality was higher in the long-course 
group than in the short-course group, both as combined 
and separate endpoints.
During the 1-year follow-up, long-course OCS was asso-
ciated with a significantly increased risk of the composite 
of pneumonia hospitalisation or all-cause mortality 
(adjusted HR [aHR] 1.3, 95% CI 1.1 to 1.4; p<0.0001), 
pneumonia hospitalisation (aHR 1.2, 95% CI 1.0 to 1.3; 
p=0.0110) and all-cause mortality (aHR 1.8, 95% CI 1.5 to 
2.2; p<0.0001) as compared with the short-course group 
(tables 2 and 3).
sensitivity analyses
As part of the sensitivity analyses, all pneumonia and 
death events were removed up to day 30 and all analyses 
for the primary endpoint were repeated, which showed 
consistent results (table 2). With this sensitivity analysis, 
we wanted to exclude the possibility that it was not the 
increased risk the first month that was responsible for 
the continued risk of pneumonia or all-cause mortality 
1 year after, that is, remove an ‘acute illness factor’ as a 
possible driver of events. In a second sensitivity analysis, 
censoring patients prior to the second OCS prescription 
showed consistent results for pneumonia hospitalisation, 
from OCS exposure to 1-year follow-up (aHR 1.1, 95% 
CI 1.0 to 1.3; p=0.1102), using the short course as a refer-
ence (table 4).
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Table 4 Sensitivity analyses: censoring and nested case–
control design
Time from exposure Adjusted HR ()/OR (95% CI)
Pneumonia (aHR)* 1.1 (1.0 to 1.3)
Pneumonia (OR)† 1.4 (1.2 to 1.7)
All-cause mortality (OR)‡ 2.4 (1.9 to 2.9)
*Analyses of long vs short oral corticosteroid (OCS) courses in all 
patients, censored prior to the second OCS course, 1-year follow-
up. Analyses were adjusted for age, sex, inhaled corticosteroids, 
smoking status, calendar year, FEV1% predicted, Medical 
Research Council Dyspnoea Scale, body mass index, heart failure, 
atrial fibrillation, myocardial infarction, hypertension, diabetes 
mellitus, peripheral vascular disease, cerebrovascular disease, 
renal failure and depression.
†Estimated OR for pneumonia hospitalisation in a nested case–
control design, 1 year before the index date. Matched on age, sex, 
FEV1% predicted and smoking.
‡Estimated OR for all-cause mortality in a nested case–control 
design, 1 year before the index date. Matched on age, sex, FEV1% 
predicted and smoking.
In a third sensitivity analysis, a nested case–control 
model was applied to calculate the OR for pneu-
monia hospitalisation. The analysis comprised 4429 
patients (2695 cases of pneumonia and 1734 controls 
without pneumonia). The sample size was less than the 
initial cohort due to the matching of age, sex, FEV1% 
predicted, smoking and index date. The estimated OR 
for the pneumonia hospitalisation was 1.4 (95% CI 1.2 
to 1.7; p=0.0004) for the long-course group, using the 
short-course group as a reference. The same analysis for 
all-cause mortality (n=4476) was 2.4 (95% CI 1.9 to 2.9; 
p<0.0001) for the long-course group. These results were 
similar to the main analyses.
dIscussIon
The main findings of our study are that the use of a long 
course of OCS in outpatients with AECOPD increased 
the risk of pneumonia hospitalisation and all-cause 
mortality within a 1-year period from the start of treat-
ment compared with the short course of OCS. Past use 
(up to 1 year before the index date) in the nested case–
control model was also associated with an increased risk 
in the long-course group for both hospitalisation with 
pneumonia and all-cause mortality. There was a time-de-
pendent change in the magnitude of risk: those with 
current exposure demonstrated a higher vulnerability 
to pneumonia and all-cause mortality. Several sensi-
tivity analyses confirmed these results. These findings 
are important given the global burden of COPD, the 
frequent use of OCS in patients with COPD exacerba-
tions and the many adverse effects to this medication. 
These observations suggest a more restrictive use of OCS 
for outpatients with AECOPD.
Because of their known efficacy in COPD, OCS are 
likely to be used frequently, and it is important for clini-
cians to know the risks associated with this therapy. 
Although the association between OCS and admission 
with pneumonia and all-cause mortality in COPD is 
poorly understood, the association has been investigated 
in other chronic diseases like rheumatoid arthritis (RA) 
and inflammatory bowel disease (IBD). A study reported 
that OCS predisposes elderly patients with IBD to bacte-
rial, fungal and protozoal infections. The rate of serious 
infections was significantly higher in patients with IBD 
who were exposed to OCS any time during the 6-month 
period before the index date as compared with non-users 
(adjusted rate ratio [aRR] 2.3, 95% CI 1.8 to 2.9). Those 
currently exposed (within 45 days) had a higher risk 
(aRR 2.8, 95% CI 2.1 to 3.7).18 For patients with Crohn’s 
disease who are enrolled in the TREAT registry, which 
is a prospective observational research programme, OCS 
significantly increased the subsequent risk of serious 
infections and any infection that required hospitalisation 
in the 6-month period before the event (aHR 1.6, 95% 
CI 1.2 to 2.1) and death (aHR 1.8, 95% CI 1.3 to 2.5).19 
Another population-based study showed an increased risk 
for admission with pneumonia for a prednisone dose of 
5 mg daily (HR 1.4, 95% CI 1.1 to 1.6) with a higher risk 
associated with doses greater than 10 mg, daily (HR 2.3, 
95% CI 1.6 to 3.2) in patients with RA.20 Most of these 
results are consistent with our findings.
A recent observational study (n=327 452) found that 
the short-term use of OCS (median days=6) was associ-
ated with an increased risk of sepsis (incidence ratio [IR] 
5.3, 95% CI 3.8 to 7.4), venous thromboembolism (IR 
3.3, 95% CI 2.8 to 3.9) and fractures (IR 1.9, 95% CI 1.7 
to 2.1) within 30 days of initiation, even at relatively low 
doses.21
Regular long-term use of OCS in COPD has been linked 
to mortality.22 A recent study showed that patients with 
COPD (N=444) that had been randomised to the conser-
vative treatment arm in the National Emphysema Trial 
had an increased risk for death (HR 1.73, 95% CI 1.25 to 
2.41; p=0.001) in the long-term corticosteroid group.23 
However, data regarding the correlation between the 
short course of OCS on mortality in patients with COPD 
are sparse.
In an attempt to minimise confounding by indication, 
we selected the short-course OCS as the comparator 
group. This was only possible because the GOLD recom-
mendations for the duration of OCS treatment changed 
from 7 to 10 days to 5–7 days in 2014. Thus, we could 
examine a cohort of patients receiving a long-course or 
short-course treatment, but the reason for choosing long 
or short OCS treatment was by recommendation and not 
by disease severity.
This is the first study with sufficient power that has 
assessed the impact of the OCS recommendation change 
on the risk of pneumonia hospitalisation and all-cause 
mortality in outpatients with AECOPD. By adjusting for 
several potential confounders, we were able to provide 
results that may better represent the magnitude of the 
association between OCS and the risk of pneumonia 
hospitalisation and all-cause mortality in a large unse-
lected COPD population. Another strength of this study 
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is that the OCS prescriptions issued in Denmark have 
high levels of completeness and accuracy.16
Some limitations should be considered while inter-
preting our findings. The primary limitation of this study 
is its observational design. Therefore, we cannot provide 
evidence of causation. However, several aspects of our 
findings support a potential causal association between 
long course of OCS and risk of pneumonia hospitalisa-
tion and all-cause mortality. While the baseline charac-
teristics of the groups were similar, it is impossible to 
account for other possible confounders that could have 
affected the results. Second, the OCS data were based on 
prescriptions and check of prednisolone adherence was 
not possible. Thus, the true use of the drug is unknown 
and may result in some bias. Third, physician decisions 
regarding the choice of long course and short course may 
have been influenced by initial illness severity, as OCS 
use itself may be a marker of disease severity. However, 
time trends and the change in guidelines diminish this 
concern. The ratio of short to long treatment courses 
increased progressively after 2014 due to the new GOLD 
recommendation (online supplementary figure s3). 
However, already between 2011 and 2013, the number of 
short courses was increased. A possible explanation could 
be an increased awareness about the side effects of OCS 
and limited effect of OCS on long-term outcomes (death 
and lung function) among physicians prior to guideline 
change. Finally, our analyses were limited to outpatients 
and our results should not be generalised to more severe 
patients. To our knowledge, this is the first time long-term 
consequences of high doses of OCS have been investi-
gated in a large-scale study with a complete long-term 
follow-up. Long courses of OCS in patients with COPD 
seem to have serious long-term adverse effects including 
a prolonged risk of pneumonia and even an increased 
risk of death. This supports increasing cautiousness by 
physicians when administering OCS to these patients 
and, whenever possible, to choose short courses rather 
than long courses. Additionally, our findings may prompt 
the development of personalised medicine strategies like 
eosinophil-guided OCS therapy.24 25
Future studies should focus on testing our results 
and investigating the possible causes of the increased 
all-cause mortality that is associated with long courses 
of OCS. Additionally, randomised trials should test 
strategies for safely administering OCS at the lowest 
possible accumulated dosage to achieve the docu-
mented positive short-term effects of OCS in COPD 
exacerbations without increasing the risk of serious 
long-term consequences. This could include blood 
eosinophils at presentation.24 So far, no data are avail-
able with regards to the minimal necessary OCS dose in 
an outpatient treatment setting. The development of 
several biological inhibitors of inflammatory mediators 
in COPD for targeting the cytokine/chemokine-medi-
ated inflammation in COPD have provided little or no 
evidence of therapeutic effectiveness with regards to 
clinical outcomes in COPD.26
conclusIon
In conclusion, long course of OCS was associated with 
increased risk of pneumonia hospitalisation and all-cause 
mortality compared with the short course of OCS. Those 
with current exposure demonstrated a higher vulner-
ability to pneumonia and all-cause mortality. Under-
standing how risk depends on patterns of OCS will 
contribute to improved benefits and harm assessment. 
Importantly, causal inference cannot be drawn from 
these observational data.
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